Noetik co-founders: CEO Ron Alfa (L) and CSO Jacob Rinaldi

Ex­clu­sive: Two ex-Re­cur­sion lead­ers start Noetik in a bid to fix the bro­ken fun­nel in can­cer drug re­search

Two for­mer lead­ers of Re­cur­sion Phar­ma­ceu­ti­cals have start­ed their own biotech start­up, hop­ing to bring a sim­i­lar da­ta-ob­sessed men­tal­i­ty to can­cer re­search.

The San Fran­cis­co-based com­pa­ny called Noetik launched Thurs­day, an­nounc­ing a $14 mil­lion seed round led by DCVC. Its two co-founders are CEO Ron Al­fa, for­mer­ly head of re­search at Re­cur­sion, and CSO Ja­cob Ri­nal­di, who pre­vi­ous­ly led on­col­o­gy re­search at the Utah biotech.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.